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Abstract 
Eukaryotic cells undergo chromosome shortening during each cell division due to the inability of 
DNA polymerase to replicate chromosome ends. This end replication problem is counteracted by 
the ribonucleoprotein telomerase, which functions as a reverse transcriptase to add DNA repeats 
to chromosome ends. These DNA repeats, called telomeres, delay cellular senescence and recruit 
DNA binding proteins which protect chromosome ends and distinguish them from double-strand 
breaks. Telomere attrition is thought to function as a means of tumor suppression as cells can 
only undergo a limited number of divisions in the absence of telomerase or an alternative 
mechanism for replenishing DNA at chromosome ends. In multicellular organisms, telomerase is 
present and active during the early stages of development, but is later downregulated, resulting in 
little or no activity in most somatic cell types. In contrast, approximately 90% of cancer cells do 
have detectable telomerase activity. This discovery has identified telomerase components, and 
other molecules regulating telomerase function, as potential targets for cancer treatment. Unlike 
multicellular organisms, single-celled organisms, such as the fission yeast Schizosaccharomyces 
pombe, are widely believed to constitutively express telomerase, despite insufficient studies on 
expression or activity in this species outside of typical laboratory conditions. Surprisingly, we 
have observed that the level of telomerase reverse transcriptase (Trt1) protein in this organism 
decreases in cells which have been arrested by entry into stationary phase, which corresponds 
with a decrease in in vitro telomerase activity from these cells. This decrease in Trt1 level is 
similarly observed in cells which have been starved of nitrogen or glucose, and the rate of 
turnover appears to be quite rapid. The downregulation of Trt1 protein is independent of trt1 
mRNA transcript level, and regions within the protein coding sequence appear to be sufficient 
for causing the observed decrease in expression. These results indicate that telomerase reverse 
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transcriptase expression in the fission yeast S. pombe is regulated in nutrient-starved cells, likely 
through degradation of the protein, as triggered by multiple protein sequence or structural 
elements. Further studies in this model organism will likely reveal great insights into 
mechanisms and functions of telomerase regulation.  
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I. Introduction 
I.1. Telomerase and the end replication problem 
DNA, the molecules that encode genetic information, must be copied in a semi-
conservative manner in order to pass information from one cell to the next generation. This 
process, known as DNA replication, requires the use of DNA polymerases to synthesize the new 
DNA strand. To initiate DNA replication, DNA polymerase requires the presence of an RNA 
primer, which is later degraded and usually replaced by DNA. However, at the ends of 
chromosomes – the linear DNA structures in eukaryotic organisms – this primer is unable to be 
replaced, which results in chromosome shortening with each successive generation. This is 
known as the end replication problem [5-7]. Most eukaryotic organisms counteract this problem 
with the reverse transcriptase telomerase, which reverse-transcribes an RNA template to add 
DNA repeats, called telomeres, to the ends of chromosomes [8, 9]. Cells which lack sufficient 
telomerase activity undergo telomere shortening following each cell division. When telomeres 
reach a critical length, they can trigger DNA damage responses and lead to cellular senescence, 
unless an alternative method of chromosome end maintenance is established [10-12]. In addition 
to their role in preventing chromosome end shortening, telomeric DNA can recruit specialized 
proteins which protect chromosome ends from being recognized as DNA double-strand breaks 
[13-15]. 
 At its core, telomerase consists of a reverse transcriptase subunit (TERT in mammals, 
Trt1 in S. pombe [2]) and an RNA subunit (TR in mammals [16], Ter1 in S. pombe [17, 18]), 
which provides a template for reverse transcription and telomeric repeat addition. Both subunits 
are limiting and haploinsufficiency has been demonstrated in mammals [19, 20] and yeast [21], 
resulting in telomere shortening. In addition, levels of the telomerase complex must be limiting 
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in order to prevent over-elongation of telomeres [22]. These observations indicate that 
telomerase expression and activity must be highly regulated in order to maintain a desired 
telomere length.  
 
I.2. Regulation of telomerase activity 
 Due to the defects observed when cells over- or under-express telomerase, it seems 
necessary that cells try to maintain tight control over telomerase activity. Indeed, multiple 
mechanisms have been implicated in the regulation of telomerase activity (reviewed in [23]). In 
multicellular organisms, telomerase activity is required in all tissues early in development, but is 
later lost in most somatic cell types [24]. In addition, telomerase activity is thought to be 
regulated under various cellular conditions, such as through the cell cycle or when the cells are 
under stress induced by DNA damage [25, 26] 
 In most adult tissues, telomerase activity is thought to be downregulated through the 
expression of core subunits [23]. While the telomerase RNA subunit can be detected in many 
human primary cells lacking telomerase activity [27], hTERT expression often mirrors 
telomerase activity, and ectopic expression of hTERT is often sufficient for restoring activity and 
elongating cellular life-span [28]. Together, these results suggest that hTERT expression is likely 
a key determinant for the presence of telomerase activity. 
Due to its essential role in telomerase function, many labs have tried to understand the 
mechanisms controlling hTERT expression. The hTERT promoter region has been extensively 
analyzed and is presumably regulated by many transcription factors, including inducers involved 
in cell proliferation and tumor suppressors, suggesting that multiple mechanisms likely 
11 
 
contribute to the controlled expression of this protein [29-31]. In addition to promoter regulatory 
elements, heterochromatin modifications likely play a significant role in telomerase expression, 
including histone modifications and CpG methylation [31-33] (For reviews on hTERT and hTR 
gene expression, refer to [34] and [35]). Despite the apparently high level of regulation of 
telomerase gene expression, telomerase activity can still be absent in cells expressing both hTR 
and hTERT mRNA, suggesting that transcription is not the sole point of telomerase regulation 
[36]. One such mechanism may involve multiple alternative splice variants of hTERT. Many of 
these produce inactive forms of the protein and may act as dominant negative isoforms, a 
regulatory mechanism that may be linked to differences in activity observed in various cell types 
[31, 37-40]. 
In addition to the control observed in embryonic development, telomere repeat addition 
has been observed to be linked to the cell cycle, as telomerase activity occurs concurrently with 
telomere replication in late S-phase [25, 41]. This cell cycle-dependent activity at telomere ends 
is thought to be regulated largely through intranuclear trafficking of telomerase [42], likely 
through telomerase-associated accessory factors [43, 44]. Expression of telomerase components 
may also be regulated through the cell cycle. For example, the promoter region of the telomerase 
RNA component in budding yeast, TLC1,  appears to recruit transcription factors which appear 
to alter expression throughout the cell cycle, increasing expression during S-phase [45]. In 
humans, TERT appears to associate with the degradation machinery in a cell cycle-dependent 
manner [46]. Sub-nuclear trafficking may also play a role in regulating telomerase activity in 
response to DNA damage, which is thought to prevent the de novo addition of telomere repeats 
to double-strand breaks [47] resulting in chromosome instability [48], as hTERT appears to be 
sequestered to nucleoli under these conditions [26]. Telomerase activity is also thought to be 
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modulated through phosphorylation by kinases linked to cell proliferation or DNA damage 
responses [49, 50]. 
The apparent complexities of telomerase regulation open the door for many potential 
problems. In fact, misregulation of telomerase activity can result in a series of complex 
disorders. 
 
I.3. Telomerase-associated disorders 
A spectrum of telomere disorders have been identified, which can occur as autosomal-
dominant, recessive, or X-linked mutations to telomerase components or genes involved in the 
biogenesis or function of telomerase (reviewed in [51]). One of the best characterized telomere 
defect disorders is dyskeratosis congenita. This disorder is initially characterized by nail 
dystrophy, skin hyperpigmentation, and oral leukoplakia, and typically results in premature 
mortality which often resemble features of age-related diseases [52]. Other telomerase-related 
diseases include pulmonary fibrosis, aplastic anemia, and liver cirrhosis [53-56]. Furthermore, 
telomere length has been observed to be a heritable trait that can increase the chance of 
developing telomere defect-associated disorders [57]. These disorders are suggestive of defects 
in highly proliferative tissues, including epidermal and hematopoietic stem cells as well as 
germline cells [24, 51, 58-60]. The telomere defects that contribute to these disorders have also 
been linked to an increased cancer rate in these patients [61]. 
Telomerase function is linked to development, when cell proliferation is high. Most cell 
types eventually lose activity [24], and because telomeres have also been observed to shorten in 
successive generations of replicating cells [62], it has been suggested that telomere shortening 
13 
 
may serve as a molecular clock, triggering replicative senescence [63] and effectively limiting 
the replicative capacity of cells. These inherent limitations serve an important function in the 
prevention of tumorigenesis. Indeed, telomerase activity can be detected in ~90% of cancer cells 
[64]. In fact, exogenous telomerase activity alone can increase the incidence of carcinogenesis 
[65, 66]. The origin of these cancer cells remains unclear; they may be the result of telomerase 
reactivation or a transformation of telomerase-positive cells [64]. Despite these challenges, 
telomerase has become an attractive diagnostic marker and potential therapeutic. Unfortunately, 
effective treatments designed to restrict telomerase activity have thus far remained elusive [67, 
68]. For this reason, studying the molecular processes involved in regulating telomerase activity 
and expression is essential for understanding and potentially preventing carcinogenesis. 
While much progress has been made to better understand how telomerase is regulated 
mechanistically and temporally, the complexities of these processes suggest that much is left to 
be done. Identification and characterization of the genes involved in regulating telomerase 
activity may identify therapeutic targets and reveal insights into the genetic causes for certain 
cancers and other telomere-related disorders. 
 
I.4. Thesis objectives 
 The fission yeast Schizosaccharomyces pombe serves well as a model system for the 
study of telomerase function due to a high level of conservation of the telomerase catalytic 
subunit [2] and telomeric proteins [69], in addition to the increased genetic tractability in this 
organism compared with mammalian systems [70, 71]. Despite the similarities between 
processes and components between humans and fission yeast, and the common use of this 
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organism as a model system, very little is known about telomerase regulation in S. pombe. We 
have hypothesized that telomerase expression is regulated in fission yeast and that the 
consequential misregulation is harmful to this organism. 
 The purpose of this thesis is to communicate the significance, methods, results, and 
analysis of the graduate research performed. Chapter one has outlined the importance of 
understanding telomerase regulation, as well as the current knowledge on this topic. Chapter two 
details the materials and methods used to carry out the research described in Chapter three. 
Chapter three describes the results obtained during the course of graduate study regarding 
conditions in which Trt1 protein expression is observed to decrease, and insight into the 
mechanisms that underlie these changes. Finally, chapter four analyzes these results and places 
them in the context of the current state of the field, as well as the future directions this work 
invites. 
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Strain name Genotype
PP60A h
+
/h
-
 leu1-32 /leu1-32   ura4-D18 /ura4-D18  
his3-D1 /his3-D1   ade6-M210 /ade6-M216  
trt1
+
/trt1 ::ura4  
PP138 h
-
  ade6-M216   leu1-32    ura4-D18   his3-D1 
PP265 h
-
PP298 h
-
  ade6-M210   leu1-32    ura4-D18   his3-D1  
trt1-Cmyc9
PP573 h
-
  trt1-Cmyc9
PP889 h
+
 leu1-32  ura4-D18   his3-D1   ade6-M210  
trt1::ura4   aur1 :aur1
r
:nda2-trt1-Cmyc9
PP903 h
-
  aur1 :aur1
r
:nda2-trt1-Cmyc9
PP922 h
-
  aur1 :aur1
r
:trt1-Cmyc9
PP924 h
-
  aur1 :aur1
r
:trt1aa290-988-Cmyc9
PP925 h
-
  aur1 :aur1
r
:trt1aa323-625-Cmyc9
PP926 h
-
  aur1 :aur1
r
:trt1aa490-988-Cmyc9
PP927 h
-
  aur1 :aur1
r
:trt1aa625-882-Cmyc9
PP928 h
-
  aur1 :aur1
r
:trt1aa1-210-Cmyc9
II. Materials and Methods 
II.1. Strains and constructs 
 
 
 
 
 
 
 
 
 
 
Genotypes of strains used in these studies are listed in Table 2.1. nda2-trt1 construct was 
created by PCR amplifying trt1 cDNA from pRH5 (lab stock) using primers BLoli3661 
(GCATTTACATTCGTTATTATCACAAATTATGACCGAACACCATACCCC) and BLoli3662 
(CGTATAAAAGCGATTATTGGATAAATTAGCGGCCGCCTGTCG). This product was then annealed to 
~500 nt of upstream and downstream sequences from nda2, which were amplified from PP138 
genomic DNA using BLoli3678 (CAGGGGCCCTCTTTTGTCGGGCTAAACGC) and BLoli3664 
(GGGGTATGGTGTTCGGTCATAATTTGTGATAATAACGAATGTAAATGC) for upstream sequence and 
Table 2.1. Strains used in 
this study. Strain names and 
corresponding genotypes 
used in experiments for this 
study are shown. 
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BLoli3680 (CAGCTCGAGAGGCTAATTCCGAGCAATCG) and BLoli3665 
(CGACAGGCGGCCGCTAATTTATCCAATAATCGCTTTTATACG) for downstream sequence. These 
regions have been previously characterized to contain sufficient promoter and terminator 
sequences for expression of α-tubulin [72]. These products were digested with ApaI, XhoI 
(underlined in sequences above) restriction enzymes and ligated into digested pCST159 plasmid 
(courtesy of Julia Cooper Lab). This plasmid was then digested with XcmI and inserted into the 
genome at the aur1 locus of sporulated haploid PP60 cells containing trt1::ura4 by lithium 
acetate transformation (as described in [73]) to create PP889 strain. This strain was later crossed 
with PP265 strain on Malt Extract plates (BIO 101) and sporulated to generate PP903 strain. 
Truncated Trt1 constructs were created by PCR or synthesized by GENEWIZ, along with 
700 nt of trt1 promoter sequence (determined to be sufficient for transcription in [74]) and C-
terminal 9-myc tag similar to that in PP298 strain, and ligated into KpnI, XhoI digested 
pCST159 plasmid. Plasmids were then integrated into the genome of PP265 cells at the aur1 
locus as above. Inserted sequences were verified by PCR and sequencing following strain 
construction. 
 
II.2. Culture conditions 
All liquid cultures were incubated at 32 °C with shaking. Cell density values were 
determined by counting via hemocytometer. Unless otherwise indicated, “log phase” denotes 
cells which have grown in liquid culture for a minimum of 8 hrs and were harvested at a cell 
density of between 0.5-2x10
7
 cells/ml. “Stationary phase” denotes cells which were harvested 24 
hrs after log phase cells were harvested and were generally at a cell density of 1-3x10
8
 cells/ml. 
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“Nitrogen starved cells” denotes cells which had grown into log phase in EMM, then washed 
once and resuspended with EMM without ammonium chloride. “Glucose starved cells” denotes 
cells which had grown into log phase in EMM, then washed once and resuspended with EMM 
containing 0.2 g/l dextrose. 
Media recipes: 
Yeast Extract with Supplements (YES) – 5 g/l yeast extract (Difco, VWR), 30 g/l glucose 
(VWR), 225 mg/l adenine, 225 mg/l histidine, 225 mg/l leucine, 225 mg/l uracil 
(Sigma), distilled water to 1 L 
Edinburgh Minimal Media (EMM) – 3 g/l potassium hydrogen phthalate, 4.15 g/l 
Na2HPO4x7H2O, 20 g/l dextrose, 5 g/l ammonium chloride, 1.05 g/l MgCl2.6H2O, 
14.7 mg/l CaCl2.2H2O, 1 g/l KCl, 0.04 g/l Na2SO4, 1 mg/l pantothenic acid, 10 
mg/l nicotinic acid, 10 mg/l myoinositol, 1 mg/l biotin, 0.5 mg/l boric acid, 0.4 
mg/l MnSO4, 0.4 mg/ml ZnSO4.7H2O, 0.2 mg/l FeCl2.6H2O, 40 μg/l molybdic 
acid, 0.1 mg/l KI, 40 μg/l CuSO4.5H2O, 1 mg/l citric acid (mix, BIO 101), 940 ml 
H2O (Ozarka) 
 
II.3. Denatured protein extract preparation 
S. pombe cells (1x10
8
) were lysed by vortexing with glass beads (0.5 mm diameter) in 
10% trichloroacetic acid for 8 min at 4 °C. Beads were washed with 10% trichloroacetic acid and 
precipitated proteins were collected by centrifugation at 16,000 g for 2 min. Samples were then 
washed once with acetone, dried, and proteins were suspended in 1x protein sample buffer (1x 
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Nu-PAGE LDS sample buffer, 50 mM dithiothreitol (DTT), 2% sodium dodecyl sulfate (SDS). 
Samples were heated to 75 °C for 5 min, centrifuged at 16,000 g for 30 sec, and the soluble 
fraction was stored at -80 °C (adapted from [75]). 
 
II.4. Western blotting 
 Myc-tagged Trt1 was visualized by western blot by first loading protein extracts onto 
Novex NuPAGE 6% Tris-Glycine Gels (Life Technologies) and electrophoresis was performed 
with 1x Tris-Glycine SDS Running Buffer at 120 V for 1.5 hrs. Proteins were transferred to Bio-
Rad Zeta-Probe nylon membrane in a Bio-Rad Mini Trans-Blot Cell at 0.5 A for 1.5 hrs in 
transfer buffer containing a 1:50 dilution of a 6.8 pH mixture of 1 M sodium dihydrogen 
phosphate and sodium hydrogen phosphate. The membrane was then blocked in 1X PBS (8 g/l 
NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4, 0.24 g/l KH2PO4, pH 7.4) with 1% v/v Tween 20 and 5% 
w/v milk for 45 min. Blots were then probed with anti-c-Myc (A14) rabbit polyclonal IgG 
antibody (Santa Cruz Biotechnology) at a concentration of 0.5 μg/ml in 1X PBS with 1.5% milk 
for 1.5 hrs. Blots were washed with 1X PBS + 1% Tween 20 and probed with horseradish 
peroxidase-conjugated goat anti-rabbit IgG antibody (Thermo Scientific) at a concentration of 
0.2 μg/ml in PBS containing 1.5% milk. Blots were washed with PBS + 1% Tween 20 and PBS 
and visualized by chemiluminescence via Pierce ECL 2 Western Blotting Substrate (Thermo 
Scientific) on Amersham Hyperfilm ECL (GE Healthcare Life Sciences). 
 Western blots for proteins with molecular weights of less than ~60 kDa, including α-
tubulin, Cdc2, and truncated Trt1 constructs, were performed as above with the following 
modifications: samples were loaded onto NuPAGE 4-12% Bis-Tris gels and ran with 1x 
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NuPAGE MOPS SDS Running Buffer. Proteins were then transferred to Protran BA85 
Nitrocellulose Membrane (Whatman) in transfer buffer containing 3.03 g/l Tris 14.4 g/l glycine, 
and 20% methanol at 100 V for 1 hr. Blots were probed with one of the following primary 
antibodies: mouse monoclonal anti-α-tubulin antibody (Sigma-Aldrich) diluted 1:20,000; mouse 
monoclonal anti-CDK1 (Cdc2) antibody (Abcam) at 0.1 μg/ml; rabbit polyclonal anti-Ccq1 
antibody produced by Open Biosystems from purified protein diluted 1:10,000; or anti-c-Myc 
antibody as above. Secondary antibodies used included HRP-conjugated anti-rabbit antibody 
described above or horse radish peroxidase-conjugated goat anti-mouse secondary antibody 
(Thermo Scientific) at 0.2 μg/ml. Blots were visualized with ECL 2 substrate on a Typhoon 8600 
Scanner (GE Healthcare Life Sciences). Blots could be stripped with stripping buffer (15 g/l 
glycine, 1% SDS, 1% Tween 20, pH to 2.2 with HCl), washed with PBS and PBS + Tween 20 
and reprobed. Western blotting procedures adapted from protocols described in [75]. 
 
II.5. RNA preparation 
Cultures (400 ml) were grown to log phase and cells were centrifuged for 4 min at 5000g, 
washed once with cold water, and dripped into liquid nitrogen to make frozen beads. Cells were 
lysed in a 6850 Freezer/Mill (SPEX SamplePrep) with eight 2 minute cycles at a rate of ten per 
second with 2 min cooling time between cycles. Lysed cells were then transferred to 10 ml 50 
mM sodium acetate (NaOAc), 1% sodium dodecyl sulfate mixed with 10 ml of 
phenol/chloroform/isoamyl alcohol (25:24:1, equilibrated with 50 mM NaOAc pH 5.2). Samples 
were then mixed, incubated at 65 °C for 2 min, and centrifuged at 7500 rpm, 4 °C for 5 min. 
RNA samples were extracted three more times with phenol/chloroform/isoamyl alcohol, and 
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once with chloroform/isoamyl alcohol. The RNA-containing supernatant was subjected to 
ethanol precipitation and centrifuged at 7500 rpm, 4 °C for 10 min in a Beckman Coulter Avanti 
J-20 centrifuge with a JS-7.5 swinging bucket rotor. The pellets were then dried and resuspended 
in 50 mM sodium acetate (pH 5.2) (adapted from [17]). 
 
II.6. Real-time reverse-transcription polymerase chain reaction 
 10 μg (as determined by spectrophotometry) of DNase-treated (Qiagen) RNA from log 
and stationary phase cells were reverse transcribed in 15 μl samples with SuperScript III Reverse 
Transcriptase (RT) (Life Technologies) in 1x First Strand Buffer with 6.7 mM DTT, 40 u 
RNasin Plus (Promega), and 0.67 mM dNTP mix (Roche) at 55 °C for 1 hr using gene-specific 
primers at 1.67 μM: BLoli3677 (trt1 exon 1) (CGTTTGTACATCGCTTCTCAAG); BLoli3723 (trt1 
exon 5) (GGAGTCGCTTTGCTGTTTG); BLoli3675 (nda2 exon 2) (CCTTAGCGATTCCACTACCAG); 
BLoli3733 (cdc2 exon 3) (TTTACACCGTTCACTAGCTGG). Samples were then treated with 5 u 
RNase H (New England Biolabs) and polymerase chain reactions (PCRs) were performed with 2 
μl of reverse-transcribed sample in 12.5 μl samples using Power SYBR Green PCR Master Mix 
(Applied Biosystems) and 100 nM final primer concentration. BLoli3677 and BLoli3676 
(CCAAAAGCAGGATTCTTCGC) were used to amplify trt1 exon 1; BLoli3723 and BLoli3722 
(AGGCAATTTGGACTTATAAACGC) were used to amplify trt1 exon 5; BLoli3675 and BLoli3674 
(TGTTGATTGGTGCCCTACTG) were used to amplify nda2 exon 2; and BLoli3733 and BLoli3732 
(CATGGACCGAATTTCAGAAACTG) were used to amplify cdc2 exon 3. Reactions were performed 
with 10 min at 94 °C followed by 40 cycles of 15 sec at 94 °C, 15 sec at 58 °C, and 20 sec at 72 
°C. A melting curve was then collected to identify the presence of a single, expected melting 
21 
 
temperature. Analysis of trt1 exon 1 and nda2 exon 2 was performed in triplicate experiments 
from biological replicates, and trt1 exon 5 and cdc2 exon 3 was performed in triplicate 
experiments from the same sample. Data from both trt1 exons were averaged together for trt1 
expression analysis. Average values and standard deviations of cycle thresholds (Ct) from 
replicates were calculated and the difference between log and stationary phases (ΔCt) were 
calculated by subtracting the values obtained for stationary extracts from those obtained for log 
extracts. The log fold change was determined as Ea
ΔCt
 where Ea is the amplification efficiency as 
calculated from a standard curve of serial dilutions for each reaction condition. Protocol adapted 
from [76]. 
 
II.7. Genomic DNA preparation 
 Cells (~2 x 10
9
) were collected by centrifugation and washed once with water and then with Z 
buffer (50 mM sodium citrate, 50 mM sodium phosphate dibasic, 40 mM ethylenediaminetetraacetic acid 
(EDTA), pH 7.8 with sodium hydroxide). Cells were resuspended in 2 ml Z buffer containing 0.5 mg/ml 
Zymolyase (US Biological) and 2 mM dithiothreitol (DTT) and incubated at 37 °C for 1 hr. Sodium 
dodecyl sulfate (SDS) was added to 4% (w/v) and incubated at 65 °C for 10 min. Sample volume was 
then raised to 10 ml with 5X TE buffer (50 mM Tris pH 8.0, 5 mM EDTA), proteinase K (Life 
Technologies) was added to 50 μg/ml, and samples were incubated at 50 °C for 1 hr. 3 ml of 5M 
potassium acetate solution was added and samples were incubated at 4 °C for 30 min. The soluble 
fraction was isolated by three rounds of centrifugation at 3700 rpm, 4 °C for 10 min in a Beckman 
Coulter Allegra 6R centrifuge with a GH-3.8 rotor. One volume isopropanol was added to each sample, 
and nucleic acids were precipitated at -20 °C for 20 min. Samples were centrifuged at 7500 rpm, 4 °C for 
10 min in a Beckman Coulter Avanti J-20 centrifuge with a JS-7.5 swinging bucket rotor. 
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Precipitates were dried and resuspended in 500 μl 5X TE buffer containing RNase A (Fisher Scientific) at 
50 μg/ml and incubated at 37 °C for 1 hr. Nucleic acids were then extracted twice with 
phenol/chloroform/isoamyl alcohol (25:24:1, equilibrated with 5X TE), once with chloroform/isoamyl 
alcohol, and precipitated with 2.5 volumes of ethanol and 0.25 volumes 10 M ammonium acetate for 1 hr 
at -20 °C. Samples were then centrifuged, washed with 70% ethanol, dried, and resuspended in 1X TE 
buffer (adapted from [75]). 
 
II.8. Southern blotting 
 Genomic DNA was digested for 12 hrs with EcoRI (New England Biolabs) and run on a 
1% agarose gel prepared with 0.5 X TBE (45 mM Tris, 45 mM borate, 1 mM 
ethylenediaminetetraacetic acid (EDTA), pH 8.3) at 120 V for ~6 hrs. Gels were stained with 
ethidium bromide (1 μg/ml) for 30 min and visualized on a Typhoon 8600 Scanner to confirm 
equal loading. Gels were then washed with 0.25 M hydrochloric acid for 10 min, 0.5 M sodium 
hydroxide, 1.5 M sodium chloride for 30 min, and 0.5 M Tris-HCl, pH7.5, 1.5 M NaCl for 30 
min, with water rinses in between washes. Gels were then washed with 10 X saline-sodium 
citrate buffer (SSC) (1.5 M sodium chloride, 0.15 M sodium citrate, pH 7.0 with citric acid) and 
transferred to a Hybond-N+ nylon membrane (GE Healthcare Life Sciences) by capillary 
blotting. Membranes were then cross-linked with 120 mJ of ultraviolet light. Probes specific for 
telomeric sequence and the rad16 gene were generated by PCR from pTELO (lab stock) and 
wildtype genomic DNA, respectively, and labeled with [α-
32
P]dCTP using High Prime DNA 
Labeling kit (Roche). Hybridizations were performed at 65 °C in Church-Gilbert buffer [77]. 
Blots were exposed to a storage phosphor screen and visualized by Typhoon Scanner (adapted 
from [73]).  
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Figure 3.1. Trt1 expression decreases when 
fission yeast cells enter stationary phase. 
Western blots were prepared with extracts from 
cells expressing Trt1 with a C-terminal tag 
with nine c-Myc repeats (Cmyc9). Blots were 
probed with anti-c-Myc, anti-α-tubulin, anti-
Ccq1, or anti-Cdc2 antibodies. Representative 
blots are shown from biologically and 
technically replicated experiments. 
 
III. Results 
III.1. Trt1 expression is downregulated in response to nutrient starvation 
While the expression of telomerase components has been observed to be regulated in 
different cell types and different conditions in mammalian studies, little is known about if or how 
the expression of telomerase is altered in the commonly-used model organism 
Schizosaccharomyces pombe. We therefore set out to identify conditions under which expression 
of the telomerase reverse transcriptase (Trt1) subunit changes in this organism. Our lab had 
previously observed that cells which had grown into stationary phase – that is, when the cell 
density in a culture becomes too high to support further growth, largely through lack of nutrients 
[78] – had reduced in vitro telomerase activity compared with cells growing in the logarithmic 
(log) phase (Baumann Lab, unpublished). To identify the cause of this loss of activity, we 
analyzed the expression of Trt1 in stationary phase cells – determined by a decrease in cell 
replication – by western blot, and observed that the level of Trt1 protein decreases as cells grow 
into stationary phase (Fig. 3.1A). While the cell may undergo many changes that could result in a 
decrease in telomerase activity, we reasoned that the absence of Trt1 was likely a key factor and 
decided to first pursue the mechanism by which Trt1 protein expression is regulated. 
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Figure 3.2. Trt1 protein 
level decreases following 
nutrient starvation. Trt1-
Cmyc9 level was assessed in 
extracts prepared from cells 
arrested in media lacking 
nitrogen (A and B) or 
glucose (C). D) Glucose 
arrested cells were 
transferred to new, glucose 
rich media and allowed to 
continue growth (Recovery). 
Representative blots are 
shown from biologically and 
technically replicated 
experiments. α-tubulin was 
used as a loading control. 
 
Similar to the response observed in cells growing into stationary phase, cells which have 
been transferred into media lacking nitrogen or glucose exhibit a decrease in Trt1 protein level 
(Fig. 3.2). This decrease appears to be quite rapid, and corresponds closely with the arrested cell 
growth (Fig. 3.2B). When glucose-starved cells are transferred to new media containing glucose, 
the level of Trt1 protein is restored quickly, and before cell replication is resumed (Fig. 3.2D). 
Similar results were seen in cells recovering from arrest induced by stationary phase or nitrogen 
starvation (data not shown). 
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Figure 3.3. Trt1 displays rapid 
turnover in response to 
cycloheximide-induced translation 
inhibition. A) Cells expressing Trt1-
Cmyc9 were treated with 160 μg/ml 
cycloheximide to block translation 
initiation. Cells were collected at the 
times indicated and extracts were then 
analyzed by western blot. B) Cells 
treated with cycloheximide were 
washed once and resuspended in new 
media and allowed to resume growth 
(Recovery). Cells were collected and 
frozen at the indicated time points and 
extracts were analyzed by western blot. 
α-tubulin was used as a loading control.  
 
To analyze Trt1 stability and turnover in rich media, cells were grown to log phase and 
arrested with the translation elongation inhibitor cycloheximide. By this method, Trt1 half-life 
was calculated to be approximately 47 min (Fig. 3.3A). This result is similar to the rate of 
turnover for Trt1 in nitrogen-starved cells (Fig. 3.2A), in which the half-life was calculated to be 
around 1 hr. Also consistent with the rate of turnover observed in glucose-starved cells (Fig. 
3.2C), when cycloheximide-treated cells are washed and resuspended in fresh media lacking the 
drug, Trt1 protein level is restored to wildtype within one hour (Fig. 3.3B). These results suggest 
that the turnover of Trt1 in cells arrested by translation inhibition via cycloheximide resemble 
cells arrested by nutrient starvation or entry into stationary phase, and may indicate a mechanism 
by which Trt1 is downregulated in these conditions. 
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In addition to the conditions discussed above, others were tested to identify possible 
environments affecting Trt1 expression. To test whether induced DNA damage could trigger a 
decrease in Trt1 protein level, cells were treated with hydrogen peroxide, hydroxyurea, or 
phleomycin at concentrations which slowed cell growth and grown into log phase. Hydrogen 
peroxide increases oxidative stress in cells, hydroxyurea depletes dNTPs, and phleomycin 
intercalates into DNA, all of which can also result in DNA breaks [79-81]. Extracts were then 
analyzed by western blot. Incubation with these drugs did not appear to have any effect on the 
level of Trt1 protein in log or stationary phase cells (data not shown). 
 
III.2. Decrease of Trt1 protein level is independent of mRNA transcript level 
To determine if trt1 mRNA transcription or stability is affected in stationary phase cells, 
qRT-PCR analysis was performed on RNA extracts from log and stationary phase cells. 
Transcript levels were normalized to total RNA concentration in each sample and the difference 
between log and stationary extracts was analyzed (Fig. 3.4). These results indicate that the level 
of trt1 transcript in these samples changes little, and in fact increases slightly in relative RNA 
abundance.  These results contrast those for nda2 and cdc2 transcripts, in which levels show 
modest decreases in relative abundance between log and stationary samples, despite no observed 
change in protein levels (Fig. 3.1). Preliminary RNA-seq data from our lab further indicates 
similar trt1 transcript levels between log and stationary phase extracts (Baumann Lab, 
unpublished). 
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Figure 3.4. Relative trt1 transcript abundance does not decrease between cells in log and 
stationary phases. RNA was extracted from cells collected in log or stationary phase and 
analyzed by qRT-PCR to detect the abundance of trt1 transcripts. RNA levels were normalized 
to total RNA as quantified by spectrometer and the ratio of stationary to log phase samples is 
shown. nda2 and cdc2 transcript levels are shown for comparison. Error bars indicate standard 
deviation from the mean. 
 
 
 
 
 
 
 
 
 
 
To further characterize the role of trt1 transcription and the roles of upstream and 
downstream sequences in Trt1 expression regulation, trt1-Cmyc9 cDNA was placed under the 
control of the α-tubulin (nda2) promoter and inserted into an unrelated region of the genome 
(aur1 locus) (Fig. 3.5A). This sequence was selected because the endogenous α-tubulin protein 
has been observed to be stable in the conditions tested (see Fig. 3.1). This construct results in a 
large increase in Trt1 protein in log phase cells (Fig 3.5B), but the level is still reduced to a 
similar degree as that seen in wildtype cells (Fig 3.5C). Similar downregulation of wildtype Trt1 
in nitrogen- or glucose-starved cells were seen in cells expressing nda2-trt1 (data not shown). 
Despite this reduction, the amount of Trt1 protein present in stationary phase nda2-trt1-
expressing cells appears to greater than expression of the wildtype protein in log phase cells (Fig 
3.5B). Cells containing only nda2-trt1-Cmyc9 are also capable of maintaining telomeres to a 
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Figure 3.5. Trt1 over-expression with the α-tubulin promoter results in regulation and 
function similar to that of the endogenous protein. A) Schematic of construct containing the 
Trt1-Cmyc9 protein coding sequence (cDNA) with ~500 nt of α-tubulin (nda2) up- and 
downstream sequences, referred to as nda2-trt1. B) Western blot analysis of wildtype (WT) 
Trt1-Cmyc9 and nda2 promoter-driven Trt1-Cmyc9 cDNA (nda2-trt1) in extracts prepared from 
cells in log or stationary (stat) phases. Juxtaposition of lanes from the same western blot are 
shown. α-tubulin was used as a loading control. C) Long and short exposures of the same anti-c-
Myc western blot are shown for wildtype and nda2-trt1 extracts (respectively) prepared from 
cells collected in log or stationary phases. Cdc2 was used as a loading control. D) Southern blot 
analysis of DNA samples from cells expressing endogenous (untagged) Trt1 (wt trt1), Trt1-
Cmyc9 (trt1-myc), or overexpressing Trt1-Cmyc9 via the nda2 promoter (nda2-trt1) after 60 or 
100 generations. Probe for rad16 was used as a loading control (LC). 
 
length similar to that seen in cells expressing wildtype Trt1-Cmyc9, with perhaps a modest 
increase in length (Fig. 3.5D). These data suggest that the trt1 coding sequence is sufficient for 
the decrease of Trt1 protein level in stationary phase cells, indicating that sequences within the 
protein coding region may be responsible for Trt1 downregulation.  
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III.3. Sequences within the Trt1 protein coding region are sufficient for downregulation 
To attempt to identify regions of Trt1 responsible for the observed decrease in Trt1 level 
in stationary phase cells, truncated constructs were created based on predicted structural domains 
suggested by Nicolas Thomä. These constructs were then placed under the control of the trt1 
promoter and expression in log and stationary phase cells was analyzed by western blot (Fig. 
3.6). Interestingly, the Trt1 N-terminus (aa1-210) is the only region tested which remains stable 
in stationary phase cells. All other regions, including non-overlapping regions, appear to be 
downregulated in stationary phase cells, although not to the same extent: aa490-988 and aa625-
882 are downregulated approximately two-fold, while aa323-625 and aa625-829 levels decrease 
to near the same degree as that of the full-length Trt1 protein. This is interesting because 
overlapping regions, notably aa625-882 and aa625-829, appear to be regulated differently, while 
non-overlapping regions, aa323-625 and aa625-829, are regulated similarly. While these results 
could be a result of the instability of expressing artificial protein constructs, they may indicate 
that multiple structural domains or sequence elements within Trt1 could be responsible for the 
decrease in protein level in the conditions analyzed.  
To attempt to identify genes or pathways involved in the stability of Trt1 or its 
downregulation in stationary phase, strains were analyzed which contained knockouts of various 
candidate genes. Candidate genes were chosen based on gene function, including genes involved 
in telomere maintenance, protein degradation, or others that may play a role in regulating Trt1 
expression (Table 3.1). These strains all appeared to have near-wildtype levels of Trt1 protein in 
log or stationary phase extracts by western blot (data not shown). While these experiments may 
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Figure 3.6. Truncated Trt1 constructs are downregulated to varying degrees in stationary 
phase cells. A) Schematic representing truncated Trt1 proteins. Trt1 truncations were designed 
to correspond with predicted structural domains (Courtesy of Nicolas Thomä Lab). Constructs 
were integrated at the aur1 locus with trt1 promoter sequence and a C-terminal 9-myc tag. 
Regions involved in telomerase RNA binding (TRB) and reverse transcription (RT) are indicated 
in the full length protein [2, 3]. B) Extracts were prepared from cells expressing truncated 
constructs in log (L) and stationary (S) phases and analyzed by western blot. Ccq1 was used as a 
loading control. 
suggest that these genes are not involved in the regulation of Trt1 expression, they cannot rule 
out the possibility of redundancies in these pathways which may negate any effects of the 
knockouts on observable differences. Therefore, more experiments are needed to identify genes 
involved in regulating Trt1 expression.  
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Gene Function
Telomere maintenance
ccq1 Telomere maintenence protein
est1 Telomerase regulator
pot1 Telomere end-binding protein
rap1 Telomere binding protein
taz1 Human TRF ortholog
ter1 Telomerase RNA
Ubiquitin ligases
pub2 HECT-type ubiquitin-protein ligase
pub3 HECT-type ubiquitin-protein ligase
rfp2 SUMO-targeted ubiquitin-protein ligase subunit
rhp6 rad6 homolog, ubiquitin conjugating enzyme E2
dbl5 Ubiquitin-protein ligase E3
dsc1 Golgi Dsc E3 ligase complex subunit
mug30 Ubiquitin-protein ligase E3
pep3
HOPS/CORVET complex subunit, ubiquitin-protein 
ligase E3
rad8 Ubiquitin-protein ligase E3
SPAC6B12.07c Ubiquitin-protein ligase E3
SPAC12B10.01c Ubiquitin-protein ligase E3
SPAC167.07c Ubiquitin-protein ligase E3
SPAC16E8.13 Ubiquitin-protein ligase E3
SPAP32A8.03c Ubiquitin-protein ligase E3
SPAPB17E12.03 Ubiquitin-protein ligase E3
SPBC14F5.10c Ubiquitin-protein ligase E3
SPBC15C4.06c Ubiquitin-protein ligase E3
SPBC16G5.03 Ubiquitin-protein ligase E3
SPBP8B7.23
Ubiquitin-protein ligase E3 implicated in 
transcription
ufd2 Ubiquitin-protein ligase E4
Miscellaneous
isp6 vacuolar serine protease
pbr1 Human CTD-binding SR-like protein rA9 homolog
pmt3 SUMO (small ubiquitin-like modifier)
pom1 DYRK family protein kinase
rdp1 RNA-directed RNA polymerase
  Table 3.1. Gene knockouts 
analyzed for effects on Trt1 
protein expression. Gene 
knockouts were generated in 
our lab or created by Bioneer 
([1]). Knockout strains were 
crossed with cells expressing 
Trt1-Cmyc9 on malt extract 
plates. Knockouts were verified 
by determining the presence of 
the selective gene and the 
absence of the target gene at 
the 5’ and 3’ ends of the gene 
coding region via polymerase 
chain reaction. Trt1 expression 
was analyzed by western blot 
using extracts from log and 
stationary phase cells. The 
genes listed appeared to have 
little to no effect on Trt1 level 
compared with expression in 
wildtype log and stationary 
phase cells (not shown). Gene 
descriptions obtained from 
PomBase [4]. 
 
32 
 
 
IV. Discussion 
The work presented here show that the expression of Trt1, the telomerase reverse 
transcriptase subunit in Schizosaccharomyces pombe, is downregulated when cell growth is 
arrested by way of entry into stationary phase or starvation of nitrogen or glucose. This 
downregulation appears to be independent of transcript level, and different regions within the 
protein coding sequence appear to be sufficient for the decrease in protein level. These results 
reveal interesting insight into the regulation of telomerase expression in fission yeast, yet more 
work is needed to fully understand the mechanisms and purposes for these complex processes. 
Knowledge in S. pombe could lead to a better understanding of the same phenomena in normal 
and cancerous human cells. 
While Trt1 protein level decreases as a result of nitrogen and glucose starvation, the 
pathways involved in this downregulation have yet to be determined. An intriguing possibility is 
that this is an example of cell cycle-regulation of telomerase expression. Nitrogen starvation 
results in arrest in G1, while glucose starvation results in arrest in G2. The Cooper Lab [82] has 
claimed that Trt1 protein level remains constant through the cell cycle in temperature-sensitive 
cell cycle mutants, but this idea likely warrants further investigation. Currently, the results shown 
here do not identify whether Trt1 expression in these conditions is regulated by the same 
pathways or different pathways. Further analyzing strains that contain knockouts and mutants in 
other genes involved in regulating cellular quiescence, such as some map kinases or the target of 
rapamycin complexes [83], or those directly involved in regulating protein expression, including 
genes involved in translation regulation or protein degradation, will likely identify the genes and 
pathways involved in the downregulation of Trt1. While the gene knockouts listed in Table 3.1 
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do not appear to be involved in the regulation of Trt1 expression, these results cannot rule out the 
possibility of redundancies in these pathways which may negate any effects of the knockouts on 
observable differences. Therefore, double mutants may be aid in identifying genes involved in 
regulating Trt1 expression. 
The results shown indicate that the mechanisms for Trt1 downregulation may involve 
protein degradation triggered by multiple sequence or structural elements. Proteins involved in 
the degradation of hTERT have been identified and suggested to play a role in cell cycle-
dependent regulation of telomerase activity [46, 84, 85]. More mutations and deletions to Trt1 
would likely reveal regions that are required for Trt1 degradation. In addition, mass spectrometry 
analysis of Trt1 may be able to identify post-translational modifications that may serve to affect 
Trt1 expression or function. Similar experiments from Trt1-immunopurified extracts may also 
reveal other proteins which interact with Trt1 to regulate expression. 
The Bähler Lab [86] has previously analyzed global RNA and protein abundance in 
growing cells and those induced to quiesce by 24 hrs of nitrogen starvation. They observed that 
overall protein abundance is reduced in nitrogen starved cells, but to a degree that is largely 
consistent with the decrease in cell volume, which is ~50%. This is in contrast with mRNA 
abundances in quiescent cells, which uniformly and globally decrease. The authors suggest that 
this disparity could be due to increased protein stability in these quiescent cells. This is of course 
in contrast to the observed expression of Trt1, the mRNA of which does not appear to decrease 
in arrested cells, while the protein level does. In addition, the authors report only a slight 
decrease in relative Pol II occupancy of trt1 mRNA between log and quiescent cells. Together, 
this research supports the ideas presented in this thesis: that the observed downregulation of Trt1 
is likely through post-translational mechanisms that may be specific to this protein or a small 
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subset of proteins that require specific regulation distinct from global protein expression and 
stability.  
The decrease in Trt1 expression under the nda2 promoter suggests that the trt1 promoter 
is not a source for downregulating Trt1 in the conditions tested. The stability of the aa1-210 Trt1 
construct in stationary phase cells under the trt1 promoter further indicates that the trt1 promoter 
is not involved in Trt1 downregulation in stationary phase cells. These results are consistent with 
the observation that the level of trt1 mRNA does not decrease in stationary phase cells, as seen in 
qRT-PCR and RNA-seq data. The nda2-trt1 construct further suggests that Trt1 protein level 
may be regulated post-translationally, as many post-transcriptional and translational regulatory 
mechanisms involve an mRNA’s 5’ and 3’ untranslated regions [87, 88].  
Increasing Trt1 expression by use of the α-tubulin promoter still results in a decrease in 
stationary phase cells, but to a level that is still above that seen in log phase cells expressing the 
Trt1 with its native promoter. This suggests that the machinery required for downregulating Trt1 
is likely being overloaded in these cells. While this does not allow us to probe the mechanisms 
by which Trt1 level decreases, it does allow us to pursue possible effects on cells that express 
Trt1 in stationary phase. Preliminary data suggests that exogenously expressing Trt1 in 
stationary phase cells via the nda2-trt1 construct (see Fig. 3.5B) does not restore telomerase 
activity in extracts (data not shown). Similarly, cells overexpressing Trt1 in log phase also do not 
have increased telomerase activity over cells expressing wildtype levels of Trt1. This is also 
suggested by the near-wildtype length of telomeres in these cells (Fig. 3.5D). These experiments 
suggest that the downregulation of telomerase activity in stationary phase is likely more complex 
than merely caused by changes in Trt1 level. This is not surprising as Trt1 is not the only 
component required for telomerase activity. Specifically, processed, functional Ter1 is likely 
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limiting in these samples. While experiments from our lab suggest that the level of processed 
Ter1 does not decrease in stationary phase, the level of spliced Ter1 appears to increase in these 
cells (Baumann Lab, unpublished), which may have a dominant negative effect on telomerase 
activity [89]. Further, these cells overexpressing Trt1 do not appear to have any growth defects 
when grown under standard laboratory conditions. Once the mechanisms involved in Trt1 
downregulation following nutrient starvation have been identified, future experiments could 
much more effectively focus on the consequences of deregulating Trt1 expression, including 
effects on telomere length maintenance and cell proliferation. 
While telomerase expression and activity appear to be tightly regulated, the implications 
for misregulation of telomerase, particularly in a single-celled organism, remain unclear. While 
regulating the expression of telomerase subunits is expected to have implications for telomerase 
activity at telomeres, other cellular processes may be affected as well. Extra-telomeric roles for 
telomerase components have been identified in mammals [90], and similar functions may be 
present in yeast. For example, human TERT has been observed to have a role as a transcriptional 
modulator in the Wnt/β-catenin signaling pathway, which is involved in many cellular processes 
including cell proliferation and differentiation [91]. Similar roles in cell growth may exist in 
fission yeast. In addition, telomerase has been observed to add de novo telomeres to DNA 
double-strand breaks, which can lead to the loss of DNA and genome instability [92, 93], 
suggesting that this is likely another condition for which maintaining low levels of telomerase 
could be vital for the cell. 
One intriguing observation is the presence of two Trt1-Cmyc9-specific bands on western 
blots (Fig. 3.1). The expected size of Trt1-Cmyc9 is approximately 132 kDa, and the two bands 
appear to run between 5 to 20 kDa apart on western blots. In addition, the ratio of the two seems 
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to change between samples, with no obvious correlation between this shift and the cellular 
conditions tested. The presence of a second band may be an artifact of the presence of the C-
terminal 9-myc tag on Trt1, but it may also be a post-translational modification or degradation 
product that holds a biological significance involving the function or regulation of Trt1. Based 
on the apparent size difference, we hypothesized that a second band could be caused by a post-
translational modification, such as monoubiquitination, or possibly proteolytic cleavage. This 
strain was further analyzed by Haering, et. al. who also describe the presence of two Trt1-Cmyc9 
specific bands, the larger of which appears more robustly in immunoprecipitation experiments, 
which lead them to believe the alternative form may be a recombination event in the myc tag 
repeats [74]. This possibility is unlikely, however, as we have not detected a mixed population of 
cells with tags of varying lengths as determined by PCR or sequencing. Thus, the cause and 
potential biological importance of this second band remains elusive. 
The results discussed in this thesis reveal the surprising result that expression of the 
catalytic subunit of telomerase, Trt1, is regulated in the fission yeast Schizosaccharomyces 
pombe, and attempts to identify the mechanisms by which said regulation occurs. Further work 
will hopefully provide a better understanding of these processes and potentially reveal 
implications relating to a series of diseases in humans. 
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